Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 217

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 217
---
 informed on a prompt basis (and in any event within 24 hours) of the status of any material developments regarding any such Acquisition Proposal and promptly provide Clearwater with copies of all documentation (as well as written summaries of any material oral communications relating to the terms and conditions of such Acquisition Proposal) received by Enfusion and its subsidiaries and their representatives relating to such Acquisition Proposal (and in any event within 24 hours of receipt thereof). Change of Recommendation As described above, and subject to the provisions described below, the Enfusion Board and Special Committee have made the recommendation that Enfusion Stockholders vote “FOR” the proposal to adopt the Merger Agreement. The Merger Agreement prohibits the Enfusion Board (or any committee thereof, including the Special Committee) from effecting an Adverse Recommendation Change (as defined below) except as described below. Neither the Enfusion Board nor any committee thereof, including the Special Committee, will take any of the following actions (any such action, an “ Adverse Recommendation Change”):

| • |     | fail to make, withhold, withdraw, amend or qualify, or publicly propose to withhold, withdraw, amend, or qualify,                                                                                     
 the recommendation that the Enfusion Stockholders adopt the Merger Agreement and approve the transactions contemplated by the Merger Agreement, including the Merger (the “Enfusion Recommendation”); |

| • |     | authorize, adopt, approve, endorse or recommend, or publicly propose to authorize, adopt, approve, endorse or 
 recommend, an Acquisition Proposal;                                                                           |

| • |     | fail to recommend against acceptance of any third party tender offer or exchange offer for the shares of Enfusion                                                                                               
 Common Stock and Enfusion Class B Common Stock within 10 business days after commencement (within the meaning of Rule 14d-2 under the Exchange Act) of such offer (or if the Special Meeting is scheduled to    
 be held within 10 business days from the date of such commencement, promptly and in any event prior to the date that is one business day before the date on which the Special Meeting is scheduled to be held); |

| • |     | adopt, approve, endorse or recommend, or publicly propose to adopt, approve, endorse or recommend, or cause or                                                                                                                                    
 permit Enfusion or any of its subsidiaries to execute or enter into any letter of intent, memorandum of understanding, merger agreement, acquisition agreement, or other similar agreement with respect to an Acquisition Proposal (other than an 
 Acceptable Confidentiality Agreement, or such other permitted confidentiality agreement under the Mer